LA MIRADA, CA--(Marketwired - Apr 15, 2013) - BioLargo, Inc. (
"We've taken our core products and expanded into a new pet line complementary to our Nature's Best Solution line," stated Dennis Calvert, BioLargo's president. "We now have a family of pet products under two brands that allows us to target the leading pet retailers as well as leading mass market retailers."
Joseph Provenzano, President of BioLargo's subsidiary Odor-No-More, Inc., through which the DEODORALL® and Nature's Best Solution® products are distributed, stated, "Our products consistently 'meet or beat' competing products in side-by-side comparisons. It's now a matter of getting the word out and getting them into consumers' hands. We believe these sales representative groups with existing relationships will give us another competitive edge as we work to develop successful selling channels."
About BioLargo, Inc.
We make life better by delivering technology-based products that help solve some of the world's most important problems that threaten our water, food, agriculture, healthcare and energy. Our website is www.BioLargo.com. Our Odor-No-More Inc. subsidiary features award-winning products serving the companion animal and equine markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. Our subsidiary, Clyra Medical Technologies, Inc., focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2013.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2012.